One-Liner
A daily-email SaaS that synthesizes FDA Warning Letters, Form 483 observations, and EMA enforcement data into a supplier risk score, alerting pharma procurement VPs before an Indian API supplier disruption reaches the drug shortage database.
AI Thinking Process
VP Supply Chain at $400M US generic pharma, 60%+ Indian API dependency. Current workflow: coordinator manually checks FDA Drug Shortage Database every Monday, skims FDA Warning Letter emails from regulatory consultant, watches Form 483 through Redica Systems, assembles monthly watch list in Excel.
TraceLink (supply chain network, has shortage intelligence feature announced 2024), IQVIA (pharma intelligence), Redica Systems (GxP compliance for regulated companies, NOT procurement buyers), GlobalData (market research), Resilinc/Everstream (generic supply chain risk, not pharma-specific), ASHP (free clinical directory, no prediction).
TraceLink is the real concern. They serve the full distribution network around serialization. Feature expansion into procurement-buyer shortage prediction is natural. G006 Feature vs Product concern applies — TraceLink could launch this as an adjacent feature within 12 months.
WHO: VP Supply Chain at US pharma manufacturer $100M-$2B revenue, heavy Indian API dependency. CURRENT: weekly Excel assembly from FDA database + consultant emails + Form 483 subscriptions. WHY-SURPRISED: data is 100% public, buyer pays $60K/year, no dedicated procurement-side shortage prediction vendor exists.
Kill reason: TraceLink platform risk (POSITIONAL — about distribution). Pivot 1: self-insured hospital systems — occupied by Vizient/Premier GPOs. Pivot 2: Indian API suppliers — no $60K/year SaaS budget.
KILLED — conviction 38%, below 50% painpoint threshold. Flavor strictness applied. Lesson: G101 applies.
Kill was POSITIONAL (distribution, not product viability). Resurrection attempted: narrow buyer to specialty-generic makers, price at $250-500K/year as Palantir-style analyst-augmented supplier intelligence.
Services-heavy model becomes a consulting firm (Alvarez & Marsal, Alira Health, ClearView Healthcare) competing with 15+ named boutiques with entrenched relationships. Doesn't cross 40%.
Kill Reason
TraceLink has a supply-chain network covering manufacturers, wholesalers, and pharmacies with shortage intelligence features announced in 2024. IQVIA has supply-chain risk analytics product lines. The procurement-buyer segment lacks a dedicated product, but the category has attracted incumbents with distribution advantage that any new entrant cannot overcome.
AI Self-Correction
↑0pts — confidence held or increased after verification
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.